HomeHome
ProductsProducts
Bioactive CompoundsBioactive Compounds
Metabolic EnzymesMetabolic Enzymes
PDEPDE
ZiritaxestatZiritaxestat

Ziritaxestat

CAS No.	1628260-79-6
MDL No.	MFCD31544330
MF	C₃₀H₃₃FN₈O₂S
MW	588.70
InChI Key	REQQVBGILUTQNN-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT→

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1628260-79-6
Product Name	Ziritaxestat

Biological Targets

ENPP2

Associated Conditions

idiopathic pulmonary fibrosis·fibrosis·systemic scleroderma

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020

PMID: 32020584 PMC: PMC7160657 DOI: 10.1111/imm.13175

Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae.

Cancers • Vol. 12, Issue 2 • 2020

PMID: 32041123 PMC: PMC7072337 DOI: 10.3390/cancers12020374

Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer.

Molecular cancer therapeutics • Vol. 19, Issue 1 • 2020

PMID: 31548293 DOI: 10.1158/1535-7163.MCT-19-0386

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).

BMJ open respiratory research • Vol. 6, Issue 1 • 2019

PMID: 31179008 PMC: PMC6530501 DOI: 10.1136/bmjresp-2019-000422

Similar Products

Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12R,19alpha)-
CAS No.162652-95-1
Vinflunine Ditartrate
CAS No.194468-36-5
Navelbine ditartrate (TN)
CAS No.125317-39-7
Vinorelbine
CAS No.71486-22-1
Vincristine Sulfate
CAS No.2068-78-2
(+)-Vincristine
CAS No.132142-73-5

Products
- CDMO Compounds
- API & Candidates
Services
CDMO & Manufacturing
Custom Synthesis
Process Development
Lab To Pilot
Commercialization
Generic APIs
CRO
Preclinical
Pharmacology & Efficacy
DMPK & Bioanalysis
Toxicology & Safety
Disease Models
Technologies
High-Potent
Chiral Synthesis
Cloud Synthesis
Fermentation
Flow Chemistry
Biocatalysis
Support
Regulatory Support
Supply Chain Solutions
About
Perspectives
Contact

HomeHome
ProductsProducts
Bioactive CompoundsBioactive Compounds
Metabolic EnzymesMetabolic Enzymes
PDEPDE
ZiritaxestatZiritaxestat

Ziritaxestat

CAS No.	1628260-79-6
MDL No.	MFCD31544330
MF	C₃₀H₃₃FN₈O₂S
MW	588.70
InChI Key	REQQVBGILUTQNN-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT→

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1628260-79-6
Product Name	Ziritaxestat

Biological Targets

ENPP2

Associated Conditions

idiopathic pulmonary fibrosis·fibrosis·systemic scleroderma

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020

PMID: 32020584 PMC: PMC7160657 DOI: 10.1111/imm.13175

Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae.

Cancers • Vol. 12, Issue 2 • 2020

PMID: 32041123 PMC: PMC7072337 DOI: 10.3390/cancers12020374

Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer.

Molecular cancer therapeutics • Vol. 19, Issue 1 • 2020

PMID: 31548293 DOI: 10.1158/1535-7163.MCT-19-0386

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).

BMJ open respiratory research • Vol. 6, Issue 1 • 2019

PMID: 31179008 PMC: PMC6530501 DOI: 10.1136/bmjresp-2019-000422

Similar Products

Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12R,19alpha)-
CAS No.162652-95-1
Vinflunine Ditartrate
CAS No.194468-36-5
Navelbine ditartrate (TN)
CAS No.125317-39-7
Vinorelbine
CAS No.71486-22-1
Vincristine Sulfate
CAS No.2068-78-2
(+)-Vincristine
CAS No.132142-73-5

Your Partner for
Complex Chemistry

About Us
Perspectives
Products
Contact

Preclinical Development
Technologies
Custom Synthesis

Ready to start your project?

Provide your target molecule or project specifications to align on a tailored development and scale-up pathway with our scientific team.

START A PROJECT

Westerstraat 10, 3016 DH, Rotterdam, The Netherlands

All products are supplied strictly for research and development use only and are not intended for human or veterinary administration, diagnostic use, or therapeutic use. Preclinical and related services are provided solely for research and development purposes and do not constitute clinical diagnosis, treatment, or veterinary care.

CLIENT PORTAL|TERMS AND CONDITIONS|PRIVACY POLICY|

Ziritaxestat

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Ziritaxestat

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Documentation

Ziritaxestat

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Related Articles

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae.

Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer.

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).

Similar Products

Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12R,19alpha)-

Vinflunine Ditartrate

Navelbine ditartrate (TN)

Vinorelbine

Vincristine Sulfate

(+)-Vincristine

Ziritaxestat

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Related Articles

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae.

Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer.

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).

Similar Products

Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12R,19alpha)-

Vinflunine Ditartrate

Navelbine ditartrate (TN)

Vinorelbine

Vincristine Sulfate

(+)-Vincristine

Documentation